1. Овечкин А.М., Свиридов С.В. Послеоперационная боль и обезбо-
ливание: современное состояние проблемы. Региональная ане-
стезия и лечение острой боли. 2006; 1: 61–75.
2. Camu F, Van Lersberghe C, Lauwers M. Cardiovascular risks and benefits
of perioperative nonsteroidal anti-inflammatory drug treatment.
Drugs 1992;44 (Suppl 5):42–51.
3. Macfarlane G. McBeth J. Silman A. Widespread body pain and mortality:
prospective population based study. BMJ. 2001, 323(7314): 662–5.
4. Zhu K, Devine A, Dick I, Prince R. Association of back pain frequency
with mortality, coronary heart events, mobility, and quality of life in
elderly women. Spine 2007; 32(18): 2012–18.
5. Wang P, Avorn J, Brookhart M, et al. Effects of noncardiovascular
comorbidities on antihypertensive use in elderly hypertensives. Hypertension
2005; 46(2): 273–9.
6. Насонов Е.Л., Лазебник Л.Б., Беленкова Ю.М. и др. Применение не-
стероидных противовоспалительных препаратов. Клинические
рекомендации. М. 2006.
7. Camu F. The role of COX-2 inhibitors in pain modulation. Drug 2003;
63 (suppl.): 1–7.
8. Bianchi M., Martucci C, Ferrario P, et al. Increased Tumor Necrosis
Factor- and Prostaglandin E2 Concentrations in the Cerebrospinal
Fluid of Rats with Inflammatory Hyperalgesia: The Effects of Analgesic
Drugs. Anesth Analg 2007;104:949–54.
9. Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen
(paracetamol) or Celecoxib Efficacy Studies (PACES): two
randomised, double blind, placebo controlled, crossover clinical trials in
patients with knee or hip osteoarthritis. Ann Rheum Dis 200; 63: 931–9.
10. Schnitzer T, Weaver A, Polis A. Efficacy of rofecoxib, celecoxib, and
acetaminophen in patients with osteoarthritis of the knee. A combined
analysis of the VACT studies. J Rheumatol 2005; 32: 1093–105.
11. Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen,
paracetamol study in osteoarthritis. A randomised comparative clinical
study comparing the efficacy and safety of ibuprofen and paracetamol
analgesic treatment of osteoarthritis of knee or hip. Ann Rheum Dis
2004; 63: 1028–35.
12. O'Donnell J, Ekman E, Spalding W, McCabe D. Analgesic effectiveness,
tolerability, and safety of celecoxib versus tramadol in patients with
chronic low back pain. ACR 2007
13. Zippel H, Wagenitz A. Comparison of the efficacy and safety of intravenously
administered dexketoprofen trometamol and ketoprofen in
the management of pain after orthopaedic surgery: A multicentre, double-
blind, randomised, parallel-group clinical trial. Clin Drug Investig,
2006; 26(9): 517–28.
14. Daniels S; Grossman E Kuss M et al. A double-blind, randomized
comparison of intramuscularly and intravenously administered parecoxib
sodium versus ketorolac and placebo in a post-oral surgery pain
model. Clin Ther. 2001; 23(7): 1018–31.
15. Radhofer-Welte S, Dittrich P, Simin M, Branebjerg P. Comparative
bioavailability of lornoxicam as single doses of quick-release tablet,
standard tablet and intramuscular injection: a randomized, openlabel,
crossover phase I study in healthy volunteers. Clin Drug Investig.
2008;28(6):345–51.
16. Grant A. Intramuscular injections in rheumatology: risks and
opportunities. Sem Hop, 1983, 59(9): 625–626.
17. Prado J, Daza R, Chumbes O et al. Antipyretic efficacy and tolerability of
oral ibuprofen, oral dipyrone and intramuscular dipyrone in children: a
randomized controlled trial. Sao Paulo Med J 2006, 124(3): 135–40.
18. Barbanoj M, Antonijoan R, Gich I. Clinical pharmacokinetics of
dexketoprofen. Clin Pharmacokinet. 2001; 40(4): 245–62.
19. Rainsford K. Nimesulide – a multifactorial approach to inflammation
and pain: scientific and clinical consensus. Curr Med Res Opin.
2006; 22(6): 1161–70.
20. Rainsford KD. Current status of the therapeutic uses and actions of
the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology
2006; 14(3–4): 120–137.
21. Kullich W, Niksic F, Klein G. Effect of nimesulide on metalloproteinases
and matrix degradation in osteoarthritis: a pilot clinical study.
Int J. Clin Pract, 2002; suppl. 128: 24–30.
22. Binning A. Nimesulide in the treatment of postoperative pain: a
double-blind, comparative study in patients undergoing arthroscopic
knee surgery. Clin J Pain. 2007; 23(7): 565–70.
23. Wober W.Comparative efficacy and safety of nimesulide and
diclofenac in patients with acute shoulder, and a meta-analysis of controlled
studies with nimesulide. Rheumatology (Oxford). 1999; 38 (
Suppl. 1): 33–8.
24. Wober W Rahlfs V Buchl N et al. Comparative efficacy and safety of
the non-steroidal anti-inflammatory drugs nimesulide and diclofenac
in patients with acute subdeltoid bursitis and bicipital tendinitis. Int J
Clin Pract. 1998; 52(3): 169–75.
25. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low
back pain with the COX-2-selective anti-inflammatory drug nimesulide:
results of a randomized, double-blind comparative trial versus
ibuprofen. Spine, 2000; 25(12): 1579–85.
26. Барскова В.Г., Якунина И.А., Насонова В.А. Применение нимеси-
ла при подагрическом артрите. Тер. архив. 2003; 5, 60–4
27. Huskisson E, Macciocchi A, Rahlfs V, et al. Nimesulide versus
diclofenac in the treatment of osteoarthritis of the hip or knee: an active
controlled equivalence study. Curr Ther Res 1999; 60: 253–65.
28. Bianchi M,M. A randomized, double-blind, clinical trial
comparing the efficacy of nimesulide, celecoxib and rofecocxib in
osteoarthritis of the knee. Drag 2003; 63 (suppl. 1): .37–46.
29. Каратеев А.Е., Каратеев Д.Е., Лучихина Е.Л. и др. Эффектив-
ность и безопасность монотерапии высокими дозами НПВП при
раннем артрите. РМЖ, 2006; 16: 24–9.
30. Laine L, Curtis S, Cryer B, et al. Assessment of upper gastrointestinal
safety of etoricoxib and diclofenac in patients with osteoarthritis and
reumatoid arthritis in the multinational etoricoxib and diclofenac
arthritis long-term (MEDAL) programme: a randomized comparison.
Lancet 2007; 369: 465–73.
31. Strom B, Schinnar R, Bilker W, et al. Gastrointestinal tract bleeding
associated with naproxen sodium vs ibuprofen. Arch Intern Med 1997;
8–22; 157(22): 2626–31.
32. Bradbury F. How important is the role of the physician in the correct
use of a drug? An observational cohort study in general practice. Int. J.
Clin. Pract. (Suppl). 2004; 144: 27–32.
33. Conforti A, Leone R, Moretti U, et al. Adverse drug reactions related to
the use of NSAIDs with a focus on nimesulide: results of spontaneous
reporting from a Northern Italian area. Drug Saf 2001; 24: 1081–90.
34. Laporte J, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding
associated with the use of NSAIDs: newer versus older agents. Drug Saf
2004; 27: 411–20.
35. Минушкин ОН. Использование препарата «Найз» у больных,
страдающих сочетанной патологией суставов и поражением
верхних отделов желудочно-кишечного тракта. Научо-прак-
тическая ревматология. 2003; 5: 72–6.
36. Каратеев А.Е., Каратеев Д.Е., Насонов Е.Л. Гастродуоденальная
переносимость нимесулида (НИМЕСИЛ, Berlin Chemie) у больных
с язвенным анамнезом: первое проспективное исследование без-
опасности селективных ЦОГ-2 ингибиторов у больных с высо-
ким риском развития НПВП-индуцированных гастропатий. На-
учно-практическая ревматология 2003; 1: 45–8.
37. Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin Pharmacokinet
1998; 35(4): 247–74.
38. Alessandrini A, Ballarin E, Bastianon A, Migliavacca C. Comparison
of the bioavailability of 2 different equal-dosage oral pharmaceutic
forms of nimesulide in healthy volunteers. Clin Ther1986;
118(3):177–82.